Co-Authors
This is a "connection" page, showing publications co-authored by Ralph R. Weichselbaum and Steven Chmura.
Connection Strength
7.633
-
Retuning the Radio in Radiobiology. J Natl Cancer Inst. 2018 04 01; 110(4):325-326.
Score: 0.641
-
Rhythmic radiotherapy beats down TGF-ß. Cell Cycle. 2017 08 03; 16(15):1391.
Score: 0.611
-
Rhythmic radiotherapy beats down TGF-ß. Cell Cycle. 2017 Aug 03; 16(15):1391.
Score: 0.611
-
Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg. 2013; 25(4):292-9.
Score: 0.479
-
Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 12 15; 133(24).
Score: 0.238
-
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
Score: 0.229
-
The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
Score: 0.216
-
Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449.
Score: 0.205
-
Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation. Semin Radiat Oncol. 2001 Oct; 11(4):338-45.
Score: 0.204
-
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
Score: 0.203
-
Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3).
Score: 0.196
-
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
Score: 0.196
-
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
Score: 0.191
-
Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
Score: 0.190
-
Coronavirus Disease 2019 Infection Prevention and Control Practices in Wuhan Radiation Therapy. Adv Radiat Oncol. 2020 Jul-Aug; 5(4):637-639.
Score: 0.186
-
Down-regulation of ceramide production abrogates ionizing radiation-induced cytochrome c release and apoptosis. Mol Pharmacol. 2000 Apr; 57(4):792-6.
Score: 0.184
-
In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42.
Score: 0.182
-
Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
Score: 0.177
-
Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
Score: 0.176
-
Strategies for enhancing viral-based gene therapy using ionizing radiation. Radiat Oncol Investig. 1999; 7(5):261-9.
Score: 0.169
-
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
Score: 0.159
-
Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res. 1997 Oct 01; 57(19):4340-7.
Score: 0.155
-
Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 1997 Apr 01; 57(7):1270-5.
Score: 0.150
-
Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
Score: 0.141
-
Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32.
Score: 0.141
-
Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012; 7(12):e50141.
Score: 0.111
-
MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011; 6(12):e28650.
Score: 0.104
-
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
Score: 0.103
-
Predictors of competing mortality in early breast cancer. Cancer. 2010 Dec 01; 116(23):5365-73.
Score: 0.095
-
Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.
Score: 0.093
-
Magnetic resonance imaging identifies multifocal and multicentric disease in breast cancer patients who are eligible for partial breast irradiation. Cancer. 2008 Nov 01; 113(9):2408-14.
Score: 0.083
-
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
Score: 0.082
-
Enhancing radiotherapy with genetically engineered viruses. J Clin Oncol. 2007 Sep 10; 25(26):4090-5.
Score: 0.077
-
Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res. 2024 May 01; 30(9):1945-1958.
Score: 0.061
-
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
Score: 0.057
-
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
Score: 0.055
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
Score: 0.051
-
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
Score: 0.050
-
Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
Score: 0.040
-
Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol. 1997 Dec; 24(6):633-8.
Score: 0.039
-
Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461.
Score: 0.036
-
Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase. Cancer Res. 1996 Jun 15; 56(12):2711-4.
Score: 0.035
-
Cross-talk between ceramide and PKC activity in the control of apoptosis in WEHI-231. Adv Exp Med Biol. 1996; 406:39-55.
Score: 0.034
-
An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol. 2014 Apr; 117(2):321-7.
Score: 0.030
-
Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013 Jun 01; 190(11):5874-81.
Score: 0.028
-
The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
Score: 0.028
-
Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):316-22.
Score: 0.027
-
Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
Score: 0.026
-
Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012 Mar; 107(1):207-12.
Score: 0.026
-
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
Score: 0.018
-
gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006 May; 6(3):197-205.
Score: 0.018